Trevi Therapeutics, Inc. (TRVI) Earnings History
Annual and quarterly earnings data from 2016 to 2025
Loading earnings history...
TRVI EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
TRVI Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export TRVI earnings history in CSV or JSON format
Free sign-in required to download data
Trevi Therapeutics, Inc. (TRVI) Earnings Overview
As of May 8, 2026, Trevi Therapeutics, Inc. (TRVI) reported trailing twelve-month net income of -$46M, reflecting +38.3% year-over-year growth. The company earned $-0.31 per diluted share over the past four quarters.
Looking at the long-term picture, TRVI's historical earnings data spans multiple years. The company achieved its highest annual net income of -$11M in fiscal 2016.
Trevi Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IDYA (-$140M net income, -52.0% margin), PTCT (-$187M net income, 39.4% margin), ACAD ($376M net income, 36.5% margin), TRVI has comparable earnings metrics. Compare TRVI vs IDYA →
TRVI Earnings vs Peers
Earnings metrics vs comparable public companies
TRVI Historical Earnings Data (2016–2025)
10 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$43M | +10.8% | -$49M | $-0.29 | - | - |
| 2024 | -$48M | -64.8% | -$52M | $-0.47 | - | - |
| 2023 | -$29M | +0.3% | -$34M | $-0.29 | - | - |
| 2022 | -$29M | +14.1% | -$30M | $-0.45 | - | - |
| 2021 | -$34M | -3.6% | -$32M | $-1.49 | - | - |
| 2020 | -$33M | -25.8% | -$32M | $-1.81 | - | - |
| 2019 | -$26M | -26.8% | -$27M | $-1.46 | - | - |
| 2018 | -$21M | -59.8% | -$18M | $-2.29 | - | - |
| 2017 | -$13M | -16.0% | -$8M | $-1.43 | - | - |
| 2016 | -$11M | - | -$9M | $-0.69 | - | - |
See TRVI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TRVI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TRVI vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTRVI — Frequently Asked Questions
Quick answers to the most common questions about buying TRVI stock.
Is TRVI growing earnings?
TRVI EPS is $-0.31, with earnings growth accelerating to +38.3%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-46M.
What are TRVI's profit margins?
Trevi Therapeutics, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are TRVI's earnings?
TRVI earnings data spans 2016-2025. The accelerating earnings trend is +38.3% YoY. Historical data enables comparison across business cycles.